HCV Testing and Treatment of Adults in the United States: 2014 Through 2021—Data From Two National Commercial Testing Laboratories
Journal of Viral Hepatitis · 2025
DOI: 10.1111/jvh.70087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2025. Verfasst von Marc G Ghany und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Hepatology Research Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of …. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis C, Hepatitis C, Chronic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Data on the hepatitis C virus (HCV) care cascade are crucial for determining if the United States (U.S.) is on track to meet 2016 World Health Organization elimination goals. De‐identified data were analysed from persons who were screened for HCV antibody and/or tested for HCV RNA by two large U.S. commercial laboratories from 1/1/2014 to 12/31/2021. Validated imputation algorithms were used to identify persons who initiated treatment and who achieved virological cure based on viral load decline and continued negative HCV RNA test results. The 3‐digit ZIP code was used to map treatment rates by U.S. state. During 1/1/2014 to 12/31/2021, a total of 46,646,661 persons were tested for HCV antibody of whom 2,253,500 (4.8%) were positive. Among 3,117,372 persons tested for HCV RNA, 1,951,742 (62.6%) were viremic. Cumulatively, a total of 672,745/1,951,742 (34.5%) viremic persons were treated; an estimated 643,043 (96%) were cured. Treatment rates increased with older age, higher fibrosis scores, HIV positivity, residing in an urban area and in the Northeast. Persons diagnosed by reflex testing had higher treatment rates. Comparing COVID‐19 pandemic (2021) to pre‐pandemic (2019) periods, 24% more HCV antibody tests were performed (10,167,524 vs. 7,727,318), but fewer persons were treated (21,136 vs. 26,124, 23% decline) and cured (19,584 vs. 24,480, 25.0% decline) in 2021, respectively. In 2021, primary care providers diagnosed and treated the greatest proportion of persons. Treatment uptake across the U.S. remains low, underscoring the need for additional measures to expand access to testing and treatment, necessary to reach the U.S. goals for HCV elimination by 2030.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Hepatology Research Section, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Health, Bethesda, Maryland, USA.
- Coalition for Global Hepatitis Elimination, the Task Force for Global Health, Decatur, Georgia, USA.
- AbbVie Inc, North Chicago, Illinois, USA.
- Gastroenterology Section, VA Long Beach Healthcare System, Long Beach, California, USA.
Förderung
- AbbVie
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ghany, M. G., Ward, J. W., Baldwin, Z., Jiao, S., Shukla, N., Kuznetsova, A., Kaur, J., Kosch, K. J., & Morgan, T. R. (2025). HCV Testing and Treatment of Adults in the United States: 2014 Through 2021—Data From Two National Commercial Testing Laboratories. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.70087
Vancouver
Ghany MG, Ward JW, Baldwin Z, Jiao S, Shukla N, Kuznetsova A, et al. HCV Testing and Treatment of Adults in the United States: 2014 Through 2021—Data From Two National Commercial Testing Laboratories. Journal of Viral Hepatitis. 2025. doi:10.1111/jvh.70087
BibTeX
@article{Ghany2025,
author = {Ghany, Marc G and Ward, John W and Baldwin, Zachary and Jiao, Shiyin and Shukla, Nidhi and Kuznetsova, Arina and Kaur, Jatinder and Kosch, Katherine J and Morgan, Timothy R},
title = {HCV Testing and Treatment of Adults in the United States: 2014 Through 2021—Data From Two National Commercial Testing Laboratories},
journal = {Journal of Viral Hepatitis},
year = {2025},
doi = {10.1111/jvh.70087}
}
EUVIMED